Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19

To evaluate the antiviral effect and safety of arbidol and Lianhuaqingwen Capsule (LH) in treating patients with Coronavirus disease 2019 (COVID-19). 108 patients with COVID-19 were divided into 2 groups, including 40 patients in the arbidol group and 68 patients in the arbidol + LH group. Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lei, Shi, Feng, Tu, Pei, Chen, Chen, Zhang, Ming, Li, Xiaoguang, Li, Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850685/
https://www.ncbi.nlm.nih.gov/pubmed/33530261
http://dx.doi.org/10.1097/MD.0000000000024475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850685/
https://www.ncbi.nlm.nih.gov/pubmed/33530261
http://dx.doi.org/10.1097/MD.0000000000024475

Ejemplares similares